Telix Pharmaceuticals Limited (TLX) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Telix Pharmaceuticals Limited (NASDAQ: TLX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $9.05 (-0.55% 1D, market cap $3.08B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TLX ranks #300 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TLX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IDYA (IDEAYA Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B) and BHC (Bausch Health Companies Inc.) posts a C+ grade (68/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.07B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
For Telix Pharmaceuticals Limited (TLX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #300 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 2.2% FCF Margin ($86.3M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While TLX currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.97) and Max Pain ($9.50) forces dealer call-delta covering toward $13.77.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Telix Pharmaceuticals Limited (TLX) slipped -0.55% to $9.05, trading at 41% of its 52-week range ($6.28 – $13.11). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
Wall Street favourites linked to heavy AI spending have been hit hard this year, as investors question how much capital mega-cap tech can keep pouring into data centres and chips. That pullback is pushing attention towar
AI spending is back in the spotlight as Wall Street rewards companies that can fund heavy technology investment from their own cash flow. That focus on internally financed growth suits fast growing Australian businesses
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TLX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TLX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Telix Pharmaceuticals Limited (TLX) ranks #300 by composite RQD confidence (47/100, grade D) and #202 by equity capitalization ($3.08B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with TLX at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TLX
ACTIVE
Telix Pharmaceuticals Limited | D | 47/100 | — | — | — | -0.55% | $3.08B | Benchmark Subject |
| IDYA IDEAYA Biosciences Inc. | E | 34/100 | — | — | -13.8% | -1.00% | $3.08B | /idya-vs-tlx → |
| BHC Bausch Health Companies Inc. | C+ | 68/100 | 21.2x | — | 7.6% | -2.19% | $3.07B | /bhc-vs-tlx → |
| DYN Dyne Therapeutics Inc. | E | 26/100 | — | — | -35.0% | +3.66% | $3.12B | /dyn-vs-tlx → |
| ELVN Enliven Therapeutics Inc. | D- | 39/100 | — | — | -26.2% | +0.86% | $3.24B | /elvn-vs-tlx → |
Telix Pharmaceuticals Limited (TLX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $3.08B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, Telix Pharmaceuticals Limited (NASDAQ: TLX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $9.05 (-0.55% 1D, market cap $3.08B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TLX ranks #300 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TLX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IDYA (IDEAYA Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -13.8%, cap $3.08B) and BHC (Bausch Health Companies Inc.) posts a C+ grade (68/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.07B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
For Telix Pharmaceuticals Limited (TLX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #300 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
TLX last traded at $9.05 (-0.55% on volume of 258,175 shares), positioning the stock -17.50% below its 50-day simple moving average ($10.97) and -8.77% below its 200-day simple moving average ($9.92). Across its 52-week range of $6.28 to $13.11, TLX sits at the 40.6% percentile with a 14-day RSI of 37.4 (NEUTRAL RANGE) and an implied next-earnings move of ±4.3% ($8.66 to $9.44).
Telix Pharmaceuticals Limited (TLX) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $9.05 (-0.55% 1D, market capitalization $3.08B).
Telix Pharmaceuticals Limited (TLX) is a NASDAQ-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $3.08B. The business operates with a gross margin of 0%, an operating margin of 0%, and a return on invested capital (ROIC) of 0% (free cash flow yield of 0%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), TLX carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Telix Pharmaceuticals Limited (TLX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Telix Pharmaceuticals Limited (TLX) market action, institutional positioning, and fundamental catalysts.
The forensic balance sheet pillar scores 13 / 20 with a Piotroski F of 6/9 and Debt/Equity of 0.5, and the 52-week range shows the price at 9.51 versus a $13.11 high.. When you look under the hood at TLX, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $13.11. My 12M target is $11.56.
@MidwestValue Agree on the RQD 47/100 quality, though with 1.0 beta I'm scaling in with half-size at $9.10 and keeping dry powder in case we test $8.46.
Here is the bear case nobody on the bull side wants to address on TLX: Whale 13F Flow scores only 5 / 20 and the cash-engine metrics (ROIC 0%, FCF yield 0%) show no current cash-return support, with a RED-flagged 12-month price target cut to $17.95.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: